Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase

Anticancer Drug Des. 1997 Jul;12(5):409-20.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Enzyme Inhibitors / pharmacokinetics*
  • Enzyme Inhibitors / toxicity*
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Oligonucleotides, Antisense / pharmacokinetics*
  • Oligonucleotides, Antisense / toxicity*
  • Protein Kinase C / antagonists & inhibitors*
  • Protein Kinase C-alpha
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-raf
  • Thionucleotides / pharmacokinetics*
  • Thionucleotides / toxicity*

Substances

  • Enzyme Inhibitors
  • Isoenzymes
  • Oligonucleotides, Antisense
  • Proto-Oncogene Proteins
  • Thionucleotides
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-raf
  • PRKCA protein, human
  • Protein Kinase C
  • Protein Kinase C-alpha